BioXcel Therapeutics has patented a method for treating agitation in subjects with Alzheimer’s Disease using sublingual administration of Dexmedetomidine. The method aims to provide anti-agitation effects within 60 minutes without causing significant sedation, offering a novel approach for neurodegenerative diseases. GlobalData’s report on BioXcel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights BioXcel Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioXcel Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. BioXcel Therapeutics's grant share as of April 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating agitation in alzheimer's disease patients

Source: United States Patent and Trademark Office (USPTO). Credit: BioXcel Therapeutics Inc

A recently granted patent (Publication Number: US11931340B2) discloses a method for treating agitation in individuals with Alzheimer's Disease by administering dexmedetomidine or its pharmaceutically acceptable salt through the oral mucosa. The method involves one or two single dosage administrations of 60 micrograms of dexmedetomidine, which should not induce significant sedation but produce an anti-agitation effect within 60 minutes post-administration. The agitation targeted in this method is specified as acute, chronic, or severe agitation, excluding perioperative agitation. The administration of dexmedetomidine can be in solid, water-soluble dosage forms such as films, wafers, or tablets, with sublingual or buccal routes being preferred.

Furthermore, the patent includes variations of the method, emphasizing the use of dexmedetomidine in film form for treating agitation in Alzheimer's Disease patients. The film can be administered sublingually or buccally, ensuring rapid onset of the anti-agitation effect within the specified timeframe. The dosage of 60 micrograms of dexmedetomidine remains consistent across the different formulations and administration routes mentioned in the claims. This patent provides a specific and targeted approach to managing agitation in Alzheimer's Disease patients, focusing on the efficacy of dexmedetomidine without causing sedation, thereby addressing a critical need in the treatment of behavioral symptoms associated with the disease.

To know more about GlobalData’s detailed insights on BioXcel Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies